National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Baricitinib (Olumiant®)

Baricitinib (Olumiant®) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.

Rapid Review

Commenced Completed Outcome
14/06/2017 13/07/2017 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

 The HSE has approved reimbursement following confidential price negotiations November 2017